Jefferies Financial Group Inc. Purchases Shares of 68,181 Evolus, Inc. (NASDAQ:EOLS)

Jefferies Financial Group Inc. bought a new position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 68,181 shares of the company's stock, valued at approximately $753,000. Jefferies Financial Group Inc. owned about 0.11% of Evolus as of its most recent SEC filing.

Several other large investors have also bought and sold shares of EOLS. KBC Group NV bought a new position in Evolus during the 4th quarter worth $49,000. China Universal Asset Management Co. Ltd. raised its position in Evolus by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after purchasing an additional 1,291 shares during the last quarter. Rhumbline Advisers raised its position in Evolus by 2.2% during the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock worth $885,000 after purchasing an additional 1,762 shares during the last quarter. Principal Financial Group Inc. raised its position in Evolus by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock worth $368,000 after purchasing an additional 2,989 shares during the last quarter. Finally, Rice Hall James & Associates LLC raised its position in Evolus by 4.8% during the 4th quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock worth $10,469,000 after purchasing an additional 43,381 shares during the last quarter. 90.69% of the stock is owned by institutional investors.

Insider Buying and Selling at Evolus

In other news, CFO Sandra Beaver sold 6,494 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $10.02, for a total transaction of $65,069.88. Following the sale, the chief financial officer now owns 167,089 shares in the company, valued at approximately $1,674,231.78. This trade represents a 3.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Karah Herdman Parschauer sold 12,888 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now owns 32,183 shares in the company, valued at $418,057.17. The trade was a 28.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,241 shares of company stock valued at $1,048,666 in the last 90 days. 6.10% of the stock is currently owned by company insiders.

Evolus Stock Performance

Shares of EOLS stock traded up $0.03 during trading on Friday, reaching $9.37. 1,595,652 shares of the company's stock traded hands, compared to its average volume of 715,251. The company has a market capitalization of $604.14 million, a P/E ratio of -10.30 and a beta of 1.11. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm's 50-day moving average is $10.61 and its 200 day moving average is $11.97. Evolus, Inc. has a 1 year low of $8.67 and a 1 year high of $17.82.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on EOLS. Barclays raised their target price on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. BTIG Research began coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Thursday, April 10th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Evolus currently has a consensus rating of "Buy" and an average target price of $23.75.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.